U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2 - Bristol Myers Squibb - News

Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor1 Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-

By: Bms.com

Dec 29 2024
0
0 Views

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab and hyaluro… [+85637 chars]

Chinese workers found in 'slavery-like conditions' in Brazil taken to hotels as probe gets underway - The Associated Press

"It's still in shambles": How Boeing can come back from crisis - BBC.com

DC-area car dealership group charged with deceiving and overcharging consumers for years - WTOP

When an anti-DEI activist took a swing at Costco, the board hit back - The Seattle Times

A 9th telecoms firm has been hit by a massive Chinese espionage campaign, the White House says - The Associated Press

Park City Mountain ski patrol goes on strike - The Park Record

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network

all our websites